Sign in Subscribe
Chairpersons

Archimedes Vascular Secures $2.2M Series A Financing, Appoints Medical Device Veteran Raymond Cohen as Chairman

Strategic Insights

— 1 min read

Archimedes Vascular, a pre-clinical stage medical device company, has closed a $2.2 million Series A financing round led by Sherpa Healthcare Partners. The investment will be used to facilitate the completion of pre-clinical work and prepare for FDA clearance for its initial human clinical study. In conjunction with the financing, Raymond W. Cohen, a veteran medical device executive, has joined Archimedes as chairman of its board of directors. Cohen brings extensive experience in navigating the clinical and FDA regulatory pathway, having previously served as CEO and board member of Nasdaq-listed Axonics, Inc.

Key Takeaways:

  • Archimedes Vascular has secured $2.2 million in Series A financing led by Sherpa Healthcare Partners, which will be used to complete pre-clinical work and prepare for FDA clearance.
  • Raymond W. Cohen, a veteran medical device executive, has joined Archimedes as chairman of its board of directors, bringing expertise in navigating the clinical and FDA regulatory pathway.
  • Cohen has previously held leadership roles at Axonics, Inc. and SoniVie, Ltd, and currently serves on the boards of Nalu Medical, Tulavi Therapeutics, Spectrum Vascular, and Kestra Medical Technologies.
  • Archimedes' implant, Barostent, is designed to induce baroreflex and treat severe hypertension in patients whose blood pressure is not controlled by pharmaceuticals or renal denervation.
  • The company holds intellectual property and has developed a delivery catheter system to support its Barostent implant.

Statistics:

  • $2.2 million: Amount of Series A financing secured by Archimedes Vascular
  • 2013: Year in which Raymond W. Cohen co-founded Axonics, Inc.
  • 2028: Year in which Cohen took Axonics public (not mentioned explicitly, but mentioned in the Financial Times ranking)
  • 2021 and 2022: Years in which Axonics ranked No. 1 on the Deloitte Technology Fast 500(TM) and the Financial Times ranking of the fastest-growing companies in the Americas
  • 2025: Year in which SoniVie, Ltd was sold to Boston Scientific Corporation (BSX)

Sources:

  • Source: Archimedes Vascular, Inc.
  • Source: Xinran Wang, Sherpa Healthcare Partners, at wangxr@sherpahp.com
  • Source: Raymond W. Cohen, rcohen@lifescience-advisors.com
  • Source: Original content to download multimedia (not cited in original text, but included for completeness)

Read more